Free Trial

BioNxt Solutions Q3 2023 Earnings Report

BioNxt Solutions logo
$0.36 -0.01 (-3.51%)
As of 02/24/2025 03:28 PM Eastern

BioNxt Solutions EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioNxt Solutions Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioNxt Solutions Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

BioNxt Solutions Earnings Headlines

BioNxt Solutions Inc.: Clarification of Promotional Activities
Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
BioNxt Solutions Inc. (BNXTF)
See More BioNxt Solutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioNxt Solutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNxt Solutions and other key companies, straight to your email.

About BioNxt Solutions

BioNxt Solutions (OTCMKTS:BNXTF) engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

View BioNxt Solutions Profile

More Earnings Resources from MarketBeat